Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $96163.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) rose 48.78% year-over-year to $96163.0, compared with a TTM value of $298888.0 through Sep 2025, up 49.09%, and an annual FY2024 reading of $223527.0, up 49.87% over the prior year.
  • Depreciation & Amortization (CF) was $96163.0 for Q3 2025 at Sunshine Biopharma, up from $72533.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $96163.0 in Q3 2025 and bottomed at $789.0 in Q3 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $33898.3, with a median of $34884.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) tumbled 75.21% in 2022, then skyrocketed 4614.83% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $3184.0 in 2021, then surged by 496.01% to $18977.0 in 2022, then soared by 123.18% to $42353.0 in 2023, then soared by 54.41% to $65399.0 in 2024, then soared by 47.04% to $96163.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for SBFM at $96163.0 in Q3 2025, $72533.0 in Q2 2025, and $64793.0 in Q1 2025.